These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23558569)

  • 41. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
    Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
    Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.
    Zheng W; Fadare O
    Int J Clin Exp Pathol; 2012; 5(3):182-6. PubMed ID: 22558471
    [No Abstract]   [Full Text] [Related]  

  • 46. Cytoplasmic Pattern p53 Immunoexpression in Pelvic and Endometrial Carcinomas With TP53 Mutation Involving Nuclear Localization Domains: An Uncommon But Potential Diagnostic Pitfall With Clinical Implications.
    Rabban JT; Garg K; Ladwig NR; Zaloudek CJ; Devine WP
    Am J Surg Pathol; 2021 Nov; 45(11):1441-1451. PubMed ID: 33899789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
    Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
    Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
    Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
    Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tubal origin of 'ovarian' low-grade serous carcinoma.
    Li J; Abushahin N; Pang S; Xiang L; Chambers SK; Fadare O; Kong B; Zheng W
    Mod Pathol; 2011 Nov; 24(11):1488-99. PubMed ID: 21701538
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.
    Bösmüller HC; Wagner P; Pham DL; Fischer AK; Greif K; Beschorner C; Sipos B; Fend F; Staebler A
    Int J Gynecol Cancer; 2017 Feb; 27(2):239-245. PubMed ID: 27984374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. p53 immunohistochemistry for distinguishing reactive mesothelium from low grade ovarian carcinoma.
    Pindzola JA; Kovatich AJ; Bibbo M
    Acta Cytol; 2000; 44(1):31-6. PubMed ID: 10667156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cervical carcinomas with serous-like papillary and micropapillary components: illustrating the heterogeneity of primary cervical carcinomas.
    Wong RW; Ng JHY; Han KC; Leung YP; Shek CM; Cheung KN; Choi CKM; Tse KY; Ip PPC
    Mod Pathol; 2021 Jan; 34(1):207-221. PubMed ID: 32699256
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
    Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
    Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia.
    Rabban JT; Vohra P; Zaloudek CJ
    Am J Surg Pathol; 2015 Jan; 39(1):35-51. PubMed ID: 25025442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
    Ritterhouse LL; Nowak JA; Strickland KC; Garcia EP; Jia Y; Lindeman NI; Macconaill LE; Konstantinopoulos PA; Matulonis UA; Liu J; Berkowitz RS; Nucci MR; Crum CP; Sholl LM; Howitt BE
    Mod Pathol; 2016 Aug; 29(8):893-903. PubMed ID: 27150160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
    O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
    Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The study of p53 and p16 immunoexpression in serous borderline and malignant ovarian tumors.
    Marinaş MC; Mogoş DG; Simionescu CE; Stepan A; Tănase F
    Rom J Morphol Embryol; 2012; 53(4):1021-5. PubMed ID: 23303027
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
    Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
    Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
    Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
    Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.